Fisetin inhibits prostate cancer cell proliferation, migration, and invasion by modulating a P-glycoprotein overexpressing multidrug-resistant cancer cell line NCI/ADR-RES. This evidence concerns the gene ABCB1 and Familial prostate cancer.